Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer

Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer

Abstract Background Endocrine therapy remains the mainstay of treatment for estrogen receptor-positive (ER+) breast cancer. Constitutively active mutations in the ligand binding domain of ERα render tumors resistant to endocrine agents. Breast cancers with the two most common ERα mutations, Y537S an...

Full description

Bibliographic Details
Main Authors: Muriel Lainé, Sean W. Fanning, Ya-Fang Chang, Bradley Green, Marianne E. Greene, Barry Komm, Justyna D. Kurleto, Linda Phung, Geoffrey L. Greene
Format: Article
Language:English
Published: BMC 2021-05-01
Series:Breast Cancer Research
Subjects:
Breast cancer
Endocrine resistant
Fulvestrant
Lasofoxifene
Selective estrogen receptor modulator
Online Access:https://doi.org/10.1186/s13058-021-01431-w

Internet

https://doi.org/10.1186/s13058-021-01431-w

Similar Items